Neoplasms

All Conditions

Heart and Blood Diseases

Rare Diseases

Glioma

Glioblastoma

Mitral Valve Insufficiency

Astrocytoma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Temozolomide

Functional MRI imaging and tomotherapy

Bassam Abdulkarim, MD

The purpose of this study is to learn whether 3 tesla (3T) MRI functional imaging will map a tumor more accurately allowing a more targeted delivery of radiation. The investigators hope to learn whether tomotherapy will be able to deliver higher radiation doses safely to the tumor while sparing the surrounding normal tissue.

Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide

Multimodality Functional Imaging (MRS and Tumor Perfusion) Predicts Tumor Migration, Invasiveness, and Patterns of Failure of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide

Cross Cancer Institute

AHS Cancer Control Alberta

Skin and Connective Tissue Diseases

Breast Neoplasms

Breast Diseases

Skin Diseases

Woo Kyung Moon, M.D., Ph.D.

The purpose of this study is:

To validate the efficacy of multiparametric MRI, FDG-PET, RGD-PET, and PET-MR fusion imaging in the prediction and monitoring response to neoadjuvant chemotherapy of locally advanced breast cancer patients.

To identify the optimal combination parameters of MR spectroscopy, diffusion-weighted MRI, dynamic contrast-enhanced MRI, FDG-PET, and RGD-PET in the prediction and monitoring response to neoadjuvant chemotherapy of locally advanced breast cancer patients.

To compare the performances of dynamic contrast-enhanced MRI using parametric response map analysis versus those of pharmacokinetic parameters (Ktrans, kep, or Ve) in the early prediction of pathological responsiveness to neoadjuvant chemotherapy in breast cancer patients

Enrolled women with breast cancers who had received an anthracycline-taxane regimen and subsequent surgery were prospectively enrolled. DCE-MRI and FDG-PET scan were performed before and after the 1st cycle of chemotherapy. MR imaging parameters and SUV on PET scan within a tumor were analyzed. Clinicopathologic (age, clinical tumor stage, hormonal receptor status, and surgery type) and imaging parameters were compared according to the pathological response.

PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer

PET-MR Fusion Imaging and Surrogate Marker for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

Pathological complete response (pCR) or non-pCR

Maximal tumor diameter measured on magnetic resonance imaging

Tumor volume measured on 3-dimensional magnetic resonance imaging

Parametric response map analysis using a software calculates the interval change of signal intensity based on a voxel-to-voxel comparison between measurements at baseline and after the first cycle of chemotherapy. PRMSI+ indicates proportions of voxels within a tumor with increased signal intensity. PRMSI- indicates proportions of voxels within a tumor with decreased signal intensity. PRMSI0 indicates proportions of voxels within a tumor with unchanged signal intensity.

Single voxel 1H-magnetic resonance spectroscopy quantifies the amount of total choline-containing compounds of a tumor, which indicates cellular proliferation and malignant transformation.

Ministry of Health & Welfare, Korea

Seoul National University Hospital

Professor

the absence of invasive tumor cells after surgery

Pathologic Complete Responders (pCR)

the presence of invasive tumor cells after surgery

Non-pCR

The absence of invasive tumor cells (ductal carcinoma in situ may have been present) after surgery.

The presence of invasive tumor cells (ductal carcinoma in situ may have been present) after surgery.

Total

40 years old or less

more than 40 years old

Age, Customized

Sex: Female, Male

Stage II

Stage III

Clinical stage (American Joint Committee on Cancer 7th edition)

Negative

Positive

Estrogen receptor

Progesterone receptor

HER2

14% or less (low proliferation)

more than 14% (high proliferation)

Ki-67 (Cellular marker for proliferation)

Hormone receptor positive

Triple negative

HER2-positive

Immunohistochemical subtype

Woo Kyung Moon

Pathologic completer Responders (pCR)

Degree of pathologic response to the neoadjuvant chemotherapy

Pathologic Response to Chemotherapy

Patholocial Response to Chemotherapy

Baseline tumor size

Post-1st chemotherapy tumor size

Tumor Size

Baseline

Post-1st chemotherapy

Tumor Volume

PRMSI+

PRMSI-

PRMSI0

Proportions of Voxels Within a Tumor With Increased or Decreased Signal Intensity (Parametric Response Map Signal Intensity; PRMSI)

Baseline Ktrans

Post-1st chemotherapy Ktrans

Constant for the Transfer of the Contrast Agent From the Plasma Compartment Into the Extracellular Extravascular Space (Ktrans)

Rate Constant of the Escape of the Contrast Agent From the Extracellular Extravascular Space Into the Plasma Compartment (Kep)

Extracellular Extravascular Space Per Unit Volume of Tissue (Ve)

Of the 48 participants, 13 participants did not undergo magnetic resonance spectroscopy examinations due to workflow problem. We included the available data from 35 participants.

Total Choline Amount of the Tumor Measured on Single Voxel 1H-magnetic Resonance Spectroscopy

Standardized Uptake Value on 18F-fluoro-deoxy-glucose Positron Emission Tomography

Overall Study

Digestive System Diseases

Symptoms and General Pathology

Behaviors and Mental Disorders

Nervous System Diseases

Rectal Neoplasms

Hypoxia

Gastrointestinal Diseases

Gastrointestinal Neoplasms

Aggression

Digestive System Neoplasms

Rectal Diseases

Colorectal Neoplasms

Intestinal Neoplasms

Intestinal Diseases

Signs and Symptoms, Respiratory

Dementia

Aberrant Motor Behavior in Dementia

Behavioral Symptoms

diffusion-weighted MRI, dynamic-contrast enhanced MRI, MR spectroscopy, blood-level oxygen dependent (BOLD) MRI

new functional magnetic resonance imaging (MRI) protocols

Kathrine Røe Redalen, PhD

The purpose of this study is to establish a reliable method for detection of rectal cancer patients with aggressive tumor at risk of metastatic disease and death by functional MRI.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide	NCT00250211	Glioblastoma Glioma	Functional MRI ...	18 Years - 65 Years	AHS Cancer Control Alberta
PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer	NCT01190566	Breast Cancer		18 Years - 70 Years	Seoul National University Hospital
Functional MRI of Hypoxia-mediated Rectal Cancer Aggressiveness	NCT01816607	Rectal Diseases Rectal Neoplasm... Gastrointestina... Gastrointestina...	new functional ...	18 Years -	University Hospital, Akershus
Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide	NCT00250211	Glioblastoma Glioma	Functional MRI ...	18 Years - 65 Years	AHS Cancer Control Alberta

Spots Global Cancer Trial Database for magnetic resonance imaging, functional